The FDA has delayed the planned big April public meeting on stem cells until later this year. Basically, the reason given is that more time is needed for stakeholders to comment. It will be interesting to see if the FDA expands the meeting beyond the 1-day format, which was going to allow each speaker only […]
Breaking: FDA postpones big stem cell public meeting Read More »
Medical News Today (MNT) published an article yesterday on a stem cell clinic in Mexico that caused a lot of concern because to many of us it came off as unbalanced and even promotional of the clinic. You can read my post from yesterday on this situation. In response, MNT has now revised their piece and included this
Revised Medical News Today Stem Cell Article Improved But Still Unbalanced Read More »
Last month the stem cell community learned that a patient of the business US Stem Cell Inc./US Stem Cell Clinic, previously known as Bioheart, had filed suit in a Broward County Florida Court against the publicly traded company alleging various charges including damage to her eye. Now US Stem Cell has more recently filed suit in the
US Stem Cell Clinic sues anonymous critics for libel, seeks IDs from websites Read More »
It’s exciting that the reviews are starting to come in on my new book, GMO Sapiens, on human genetic modification including CRISPR. Here is one from The Scientist and the book was recommended by Scientific American. Reviews from individual authors and scientists are below. “GMO Sapiens could not be more timely. New technologies like CRISPR-Cas9 gene
Reviews of my new book GMO Sapiens on #CRISPR & human modification Read More »
For the first time I have ever seen in at least half a dozen years, a major newspaper in the form of The Boston Globe has published an editorial on FDA regulation of stem cells. The editorial, entitled “It should be safety-first on stem cell therapies”, argues that while we should take patient concerns into
Historic Boston Globe editorial on FDA, stem cells & patients argues safety first Read More »
New genetic modification technology such as CRISPR-Cas9 has opened the door to transformative biological research, but it has also set the table for some novel kinds of technological problems for which we aren’t at all prepared including one that I call the “gene spill”. The striking potential upsides to CRISPR paired with some of the
A new possible environmental disaster: the gene spill Read More »
Last week I blogged about how the FDA had issued a warning letter to a series of three co-owned fat stem cell clinics across the US. What does this FDA action mean on the broader stem cell clinic arena, particularly to those selling fat stem cells? The FDA is still in the process of getting public comment
FDA warning points to tougher regulation of fat stem cells & clinics Read More »
The patent dispute on CRISPR between UC/Jennifer Doudna and The Broad/Feng Zhang has been the subject of major attention including in a recent piece on Stanford Center for Law & Biosciences Blog. There is a lot of confusion over this important CRISPR dispute so I turned to a patent expert for their take on this via an interview
Patent expert weighs in on CRISPR dispute between UC & Broad Read More »
The Nuffield Council on Bioethics has released an open call for information and comments on genetic modification, including on humans and other organisms. I strongly encourage readers to participate and voice your opinions, regardless of whether you lean toward caution or taking risks on genetic modification. Your input will be important for how the Nuffield
When I first started blogging here about stem cells in 2010, frankly it felt pretty lonely out there in cyberspace. Nature‘s great blog by Monya Baker and Natalie DeWitt on stem cells had called it quits late in 2009. For the most part the stem cell blogs and other Internet outlets present early in 2010
Best stem cell blog of 2015: CIRM’s The Stem Cellar Read More »